Polymorphism that can protect against the "diseases of aging"

Anna Stavina, XX2 century

Scientists have found that the pathological activation of NADPH oxidase (oxidase of reduced nicotinamide adenine dinucleotide phosphate), a protein complex known for its ability to cause most of the "diseases of aging", can be blocked. This discovery is theoretically able to form the basis for the creation of new medicines to combat such diseases.

The work was carried out by researchers from the University of Surrey (University of Surrey) in collaboration with colleagues from the University of Reading (University of Reading), the University of Cologne (it.Universität zu Köln) and the Royal Berkshire Hospital (Royal Berkshire Hospital). The article by Meijles et al. p22phox C242T Single-Nucleotide Polymorphism Inhibits Inflammatory Oxidative Damage to Endothelial Cells and Vessels is published in the journal Circulation.

Under the influence of metabolic stress, NADPH oxidase begins to attack blood vessels, the inner lining of the heart, joints and the brain, which leads to the development of age-related diseases. However, this enzyme complex also has a useful function. It helps cells interact with each other, so the presence of NADPH oxidase in the body is vital.

In a new study, a single nucleotide polymorphism of the C242T protein was discovered, a naturally occurring mutation that protects against cardiovascular diseases and simultaneously affects the activation of NADPH oxidase. Initially, polymorphism was found using computer modeling, but later the hypothesis was confirmed by a series of experiments on cells lining the capillaries of human lungs.

Having determined the molecular mechanism underlying the effect of C242T polymorphism, the researchers made it possible to create drugs that prevent the activation of this protein complex under stress, but do not affect its physiological functions. Scientists believe that their discovery may lead to the emergence of drugs to combat cardiovascular diseases, diabetes, arthritis, dementia and pulmonary fibrosis.

In addition, the results of the work can be used in personalized medicine. Over time, patients may be prescribed precisely adjusted doses of drugs depending on the presence of certain single-nucleotide polymorphisms in the genome.

Dr. Brendan Howlin, Head of Postgraduate Research at University of Surrey, noted: "This discovery can have a significant impact on both healthcare and individual patients, as it addresses two key problems of modern medicine: the aging of the population and the growing demands for personalized treatment. Since the first study, we have been developing a series of drugs that prevent the activation of [NADPH oxidase], and now these drugs are being prepared for market launch."

Portal "Eternal youth" http://vechnayamolodost.ru  19.12.2016